Tiba Biotech emerged in 2018 from a five-year multi-lab research initiative between the Massachusetts Institute of Technology’s Koch Institute, the Whitehead Institute, and Boston Children’s Hospital. With their international collaborators and strategic partners, Tiba is leveraging a revolutionary replicon RNA technology platform to develop safer, affordable vaccines for both human and animal health.

The core innovation is centered around a transformative RNA delivery molecule and an engineered replicon payload capable of targeted antigen expression and rapid on-demand production. With their collaborators at the U.S. Army Medical Research Institute of Infectious Diseases, they have demonstrated protection against Ebola, H1N1 and a variety of other lethal infections in a range of animal models.

Their name, Tiba, is the Swahili word for treatment or cure. On their quest toward fulfilling this vision, they embrace the core values of scientific integrity, respect for others, the pursuit of diversity and inclusion, and a passion for improving all lives across the globe.  They are building a diverse ecosystem of dedicated partners who share these values, with an underlying belief that cooperation and teamwork produce the best possible outcomes.